Abbonarsi

Two-year outcomes of balloon-occluded retrograde transvenous obliteration of gastric varices in liver transplant recipients: A multi-institutional study - 14/11/17

Doi : 10.1016/j.diii.2017.03.005 
W.E. Saad a, J.F.B. Chick a, , R.N. Srinivasa a, N. Saad b, S. Kim b, A. Fischman c, G. Frey d, A. Al-Osaimi e, S. Caldwell e
a Department of Radiology, Division of Vascular and Interventional Radiology, University of Michigan Medical Center, Michigan Medicine, 1500, East Medical Center Drive, 48109 Ann Arbor, Michigan, USA 
b Department of Radiology, Division of Vascular and Interventional Radiology, Mallinckrodt Institute of Radiology, 63110 Saint-Louis, MO, USA 
c Department of Radiology, Division of Vascular and Interventional Radiology, Mount Sinai Hospital, 10029 New York, NY, USA 
d Department of Radiology, Division of Vascular and Interventional Radiology, Mayo Clinic, 55902 Rochester, MN, USA 
e Department of Radiology, Division of Vascular and Interventional Radiology, University of Virginia Health System, 22908 Charlottesville, VA, USA 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Purpose

To assess the 2-year effectiveness and safety of balloon-occluded retrograde transvenous obliteration (BRTO) for gastric varices (GVs) in liver transplant recipients.

Materials and methods

Eleven liver transplant recipients underwent consecutive BRTO for GVs at four institutions. Patients included eight (73%) men and three (27%) women with mean age of 56 years±12 (SD) (range: 26–67 years). Underlying cause of liver transplantation was hepatitis C virus (HCV)-related cirrhosis in five (45%), alcohol- and HCV-related cirrhosis in three (27%), primary biliary cirrhosis in two (18%), and alcoholic cirrhosis in one (9%). Five (45%) patients underwent BRTO for actively bleeding GVs, three (17%) for high-risk GVs, and three (17%) for augmentation of portal venous flow through obliteration of gastrorenal shunts. Mean time between liver transplantation and BRTO was 78 months (range: 0.1–276 months). Technical success, GVs obliterative rates, and immediate complications were recorded. Post-BRTO hemorrhagic, transplant, and overall survival rates were evaluated at 6, 12, and 24 months.

Results

All (100%) procedures were technically successful. Complete GVs obliteration was achieved in ten patients (91%). Two major complications (18%) occurred in the immediate post-procedure period. One patient developed complete portal vein thrombosis, and another patient developed consumptive coagulopathy, ultimately leading to death. No post-BRTO hemorrhagic recurrences were seen at 6, 12, or 24 months. One patient (9%) had delayed upper gastrointestinal bleeding at 34 months after the procedure which was managed conservatively. Transplant and overall survival rates were 91% at 6, 12, and 24 months.

Conclusion

BRTO has high technical success and complete GVs obliterative rates in liver transplant recipients with few complications and high graft survival rates.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Balloon-occluded retrograde transvenous obliteration, Gastric varices, Liver transplantation, Liver transplant recipient, Interventional radiology

Abbreviations : BRTO, GVs, MELD, HCV, EGD, TIPS, EUS, SIR


Mappa


© 2017  Éditions françaises de radiologie. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 98 - N° 11

P. 801-808 - Novembre 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Percutaneous radiofrequency ablation of lung metastases from colorectal carcinoma under C-arm cone beam CT guidance
  • G. Amouyal, S. Pernot, C. Déan, B. Cholley, F. Scotté, M. Sapoval, O. Pellerin
| Articolo seguente Articolo seguente
  • Combined use of postmortem 3D computed tomography reconstructions and 3D-design software for postmortem ballistic analysis
  • L. Tuchtan, G. Gorincour, M. Kolopp, P. Massiani, G. Léonetti, M.-D. Piercecchi-Marti, C. Bartoli

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.